{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:42:17Z","timestamp":1786650137138,"version":"build-2736575974"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Melasma is a pigmentary disorder that typically appears on the face. Given its tendency to relapse, resistance to treatment and significant impact on social and emotional well-being, melasma poses considerable challenges.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To compare the effectiveness and adverse effects of tranexamic acid (TXA) in reducing modified Melasma Area and Severity Index (mMASI) scores when given along with microneedling versus intradermal injections in the treatment of melasma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      This was a hospital-based randomised controlled study conducted in the outpatient Department of Dermatology, Venereology and Leprosy, Aarupadai Veedu Medical College, among patients with melasma, between November 2022 and April 2024. In Group A (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 35), patients received microneedling with TXA (4 mg\/mL) and intradermal injections of TXA (4 mg\/mL) in Group B (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 35). Treatment was administered every 4 weeks for four sessions and followed-up once a month for 2 months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The baseline characteristics of the study groups did not vary significantly by age (in years), gender, Fitzpatrick skin type, precipitating factors, clinical type of melasma, and pattern of melasma. Both groups showed significant reduction in mMASI scores from baseline to 20 weeks (7.1 \u00b1 2.3 to 4.6 \u00b1 0.5 in Group A and 7.0 \u00b1 3.1 to 5.3 \u00b1 0.7 in Group B, respectively). From 12\n                      <jats:sup>th<\/jats:sup>\n                      week onwards, Group A had significantly lower mMASI scores than Group B (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05). A total of 83% of Group A patients had nearly cleared melasma compared to 37.0% in Group B (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05). Photographic documentation revealed that over 75.0% of Group A patients had more than 50.0% improvement, against 40.0% in Group B (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05). Adverse events such as erythema, pain, burning sensation, and pigmentation were slightly more common in Group B, but the difference was not statistically significant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The study highlights microneedling with TXA as a promising and effective treatment option for melasma, offering substantial clinical improvement and patient satisfaction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijd.ijd_1041_24","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T15:00:08Z","timestamp":1767970808000},"page":"109-114","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Tranexamic acid Microneedling versus Intradermal Injection of Tranexamic Acid in the Treatment of Melasma \u2013 A Randomised Controlled Trial"],"prefix":"10.4103","volume":"71","author":[{"given":"M.","family":"Srijha","sequence":"first","affiliation":[{"name":"From the Department of Dermatology, Venereology and Leprosy, Aarupadai Veedu Medical College, Vinayaka Mission\u2019s Research Foundation (VMRF-DU), Puducherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damayandhi","family":"Kaliyaperumal","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, Venereology and Leprosy, Aarupadai Veedu Medical College, Vinayaka Mission\u2019s Research Foundation (VMRF-DU), Puducherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jude Ernest","family":"Dileep","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, Venereology and Leprosy, Aarupadai Veedu Medical College, Vinayaka Mission\u2019s Research Foundation (VMRF-DU), Puducherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheela","family":"Kuruvila","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, Venereology and Leprosy, Aarupadai Veedu Medical College, Vinayaka Mission\u2019s Research Foundation (VMRF-DU), Puducherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"R1-20260227","doi-asserted-by":"crossref","first-page":"426","DOI":"10.4103\/2229-5178.142484","article-title":"Melasma update","volume":"5","author":"Sarkar","year":"2014","journal-title":"Indian Dermatol Online J"},{"key":"R2-20260227","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1097\/DSS.0000000000002520","article-title":"Clinical efficacy of topical tranexamic acid with microneedling in melasma","volume":"46","author":"Kaur","year":"2020","journal-title":"Dermatol Surg"},{"key":"R3-20260227","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4103\/ijdd.ijdd_37_17","article-title":"Tranexamic acid in melasma: Why and how?","volume":"3","author":"Dashore","year":"2017","journal-title":"Indian J Drugs Dermatol"},{"key":"R4-20260227","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/cosmetics9050108","article-title":"Mechanism of action of topical tranexamic acid in the treatment of melasma and sun-induced skin hyperpigmentation","volume":"9","author":"Maeda","year":"2022","journal-title":"Cosmet"},{"key":"R5-20260227","doi-asserted-by":"crossref","first-page":"447","DOI":"10.4103\/0378-6323.66602","article-title":"Comparative study of trichloroacetic acid versus glycolic acid chemical peels in the treatment of melasma","volume":"76","author":"Kumari","year":"2010","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R6-20260227","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4103\/0974-2077.118403","article-title":"A randomised, open-label, comparative study of tranexamic acid microinjections and tranexamic acid with microneedling in patients with melasma","volume":"6","author":"Budamakuntla","year":"2013","journal-title":"J Cutan Aesthet Surg"},{"key":"R7-20260227","first-page":"36","article-title":"Intradermal tranexamic acid injection for the treatment of melasma: A pilot study with 48-week follow-up","volume":"13","author":"Lueangarun","year":"2020","journal-title":"J Clin Aesthet Dermatol"},{"key":"R8-20260227","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4103\/0019-5154.174024","article-title":"Proposing melasma severity index: A new, more practical, office-based scoring system for assessing the severity of melasma","volume":"61","author":"Majid","year":"2016","journal-title":"Indian J Dermatol"},{"key":"R9-20260227","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s13075-016-1151-6","article-title":"Patient global assessment in measuring disease activity in rheumatoid arthritis: A review of the literature","volume":"18","author":"Nikiphorou","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"R10-20260227","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/ijd.14541","article-title":"Clinical and epidemiologic features of melasma: A multicentric cross-sectional study from India","volume":"58","author":"Sarkar","year":"2019","journal-title":"Int J Dermatol"},{"key":"R11-20260227","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1001\/archderm.1994.01690060057005","article-title":"Topical retinoic acid (tretinoin) for melasma in black patients: A vehicle-controlled clinical trial","volume":"130","author":"Kimbrough-Green","year":"1994","journal-title":"Archives of Dermatology"},{"key":"R12-20260227","first-page":"407142","article-title":"Effect of 82% lactic acid in treatment of melasma","author":"Singh","year":"2014","journal-title":"Int Sch Res Notices, 2014"},{"key":"R13-20260227","doi-asserted-by":"crossref","first-page":"12084","DOI":"10.3390\/ijerph191912084","article-title":"Understanding melasma-how can pharmacology and cosmetology procedures and prevention help to achieve optimal treatment results?A narrative review","volume":"19","author":"Pi\u0119towska","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"R14-20260227","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1590\/abd1806-4841.20143063","article-title":"Melasma: A clinical and epidemiological review","volume":"89","author":"Handel","year":"2014","journal-title":"An Bras Dermatol"},{"key":"R15-20260227","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/bjd.13059","article-title":"Risk factors for facial melasma in women: A case-control study","volume":"171","author":"Handel","year":"2014","journal-title":"Br J Dermatol"},{"key":"R16-20260227","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0190-9622(81)70071-9","article-title":"Melasma: A clinical, light microscopic, ultrastructural, and immunofluorescence study","volume":"4","author":"Sanchez","year":"1981","journal-title":"J Am Acad Dermatol"},{"key":"R17-20260227","doi-asserted-by":"crossref","first-page":"e1636","DOI":"10.1002\/hsr2.1636","article-title":"Evaluation of the effectiveness of microneedling with tranexamic acid in comparison with microneedling with vitamin C in the treatment of melasma: A prospective and single-blind clinical trial","volume":"6","author":"Pazyar","year":"2023","journal-title":"Health Sci Rep"},{"key":"R18-20260227","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1097\/DSS.0000000000002449","article-title":"Tranexamic acid for melasma treatment: A split-face study","volume":"46","author":"Ebrahim","year":"2020","journal-title":"Dermatologic Surgery"},{"key":"R19-20260227","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2147\/CCID.S142450","article-title":"Review of applications of microneedling in dermatology","volume":"10","author":"Iriarte","year":"2017","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"R20-20260227","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/jocd.15580","article-title":"Tranexamic acid microinjections versus tranexamic acid mesoneedling in the treatment of facial melasma: A randomized assessor-blind split-face controlled trial","volume":"22","author":"Poostiyan","year":"2023","journal-title":"J Cosmet Dermatol"},{"key":"R21-20260227","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4103\/2229-5178.185468","article-title":"Microneedling: Advances and widening horizons","volume":"7","author":"Singh","year":"2016","journal-title":"Indian Dermatol Online J"},{"key":"R22-20260227","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/jocd.15965","article-title":"The efficacy and safety of microneedling with topical tranexamic acid for melasma treatment: A systematic review and meta-analysis","volume":"23","author":"Feng","year":"2024","journal-title":"J Cosmet Dermatol"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_1041_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:04:08Z","timestamp":1786647848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_1041_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_1041_24","relation":{},"ISSN":["0019-5154","1998-3611"],"issn-type":[{"value":"0019-5154","type":"print"},{"value":"1998-3611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"2024-12-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}